Blank

Irbesartan pharmacokinetics

Common Questions and Answers about Irbesartan pharmacokinetics

avalide

Avatar m tn Ezetimibe was found to have a 50%inhibition conc of 25micromolar, while irbesartan, a commonly used angiotensin inhibitor to reduce blood pressure, was found to inhibit at 11.9 micromolar. Both compounds have similar MW, but irbesartan is given at up to 300mg per day, while exetimibe is dosed at 10mg. Thus the combination of 30fold higher approved dose and the double micromolar inhibition potency makes, in theory, irbesartan 60 fold more potent to inhibit Hbv entry.
Avatar n tn m currently taking Irbesartan every morning and is now controlled well. I enjoy traveling in hot conditions, some days can be up to 39 degrees. Can my blood pressure medication stand such heat if I was to say just put it in my wallet? I'm always traveling to different places and don't always have access to a fridge or ice to take on hand. If not, are there any other heat resistance BP medication i can try?
Avatar n tn - Absorption, oral: time to peak concentration 7h - Elimination half-life = 12 h (It says also that in general it can be administered once daily because it has a 24 h effect.Why?) - Can you give another example to clarify it better please? - When it says divide in 2 doses , does it mean only in the morning and dinner? 3 doses (morning-lunch-dinner)? Thank you for taking the time to answer!!
Avatar n tn Can you please advise if I am taking high blood pressure medication (irbesartan) and Altorvastatin for high cholesteron and I am also taking Tamoxafin for breast cancer (about to come off this drug), is it adviseable to take Leptin Cocoa for health weight loss or would this affect the medications?
Avatar n tn put me on lowest dose of Losartan and I got joint pain in my thumbs and then in a knee so I weaned myself off but my BP was very high (systolic) during visit. He puts me on Irbesartan, SAME class of drug, then goes on VACATION. It's the smallest dose and I took a corner of a pill yesterday, no pill today, BP is fine, I'm in PAIN. My thumbs hurt, my right foot and left knee, I don't feel well and then I read that all of this are side effects of this drug.
Avatar m tn I am a male 70 years of age. I have been on 150mg Irbesartan and 5mg Amlodipine daily since October 2010. This controlled by BP within acceptable limits. Since late April, however, the systolic has risen to an average of around 150. My doctor wants me to add a beta blocker to the other medications. Since last October my heart rate was averaging below 60. Since late April it is averaging around 70.
Avatar n tn my friend just started taking trandolapril 1mg and Irbesartan its only been a couple days but she feels awful dizzy, heart palpatations, head ache and her blood pressure is still really high 190/110 should she just stick it out?
Avatar f tn Hi, My doctor has diagnosed a mild calcification of the aortic valve and mild to moderate aortic regurgitation. I also have mild hypertension which is controlled with Irbesartan. I'm 50 and don't seem to have any symptoms but what can I expect and what can I do to improve my condition.
Avatar m tn Call your pharmacist or your doctor and ask if this is a known side effect of the med you're on. Ask if stopping has any risks, and if not, it's a good idea to stop and see if that solves your problem. Sometimes you have to taper off some meds but unless your BP is so high you're about to drop dead from it, most BP problems depending on your age and how long the problem has existed can be fixed by changing diet and lifestyle.
Avatar m tn I can't help out on the pharmacokinetics, but your reasoning is sound: it doesn't make sense to dose so that the drug runs out. I'd query Schering-Plough as well as your hepatologist, if I were you. Please give me a heads-up if you solve the riddle.
7510956 tn?1411671417 //www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm375286.
Avatar m tn Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
Avatar f tn Folic acid supplementation in folate-deficient patients with epilepsy changes the pharmacokinetics of phenytoin, usually leading to lower serum phenytoin concentrations and possible seizure breakthrough..." It however says that initiation of Folic acid and phenytoin together is beneficial. Since you can't go back and start all over again, you can take a small dose. It has been observed that as los as 1mg dose can perturb phenytoin’s levels, You may take doses lower than 1mg/day.
863754 tn?1239144755 However, physiological changes resulting from smoking cessation may alter the pharmacokinetics or pharmacodynamics of insulin; dosage adjustments may be necessary.
Avatar m tn The Phase 1 trial was designed to characterize the safety profile of ARC-520 across a range of doses and evaluate pharmacokinetics. It is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers. All subjects have been dosed and received either placebo or ARC-520 in doses ranging from 0.01 mg/kg to 2 mg/kg.
Avatar f tn i believe in the pre-clinical trials with healthy volunteers, researchers used Carbon14 to gauge the half-life and paths of elimination during pharmacokinetics studies. it is a common practice. perhaps that is what you are thinking about?
29837 tn?1414534648 The pharmacokinetics of ledipasvir were studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe hepatic impairment (Child-Pugh Class C). Ledipasvir plasma exposure (AUC0-inf) was similar in subjects with severe hepatic impairment and control subjects with normal hepatic function. Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis had no clinically relevant effect on the exposure of ledipasvir [see Use in Specific Populations (8.
808353 tn?1238293321 The combination of two potent direct-acting antivirals (DAAs), targeting two distinct viral enzymes, may offer advantages over single DAA strategies by enhancing potency, reducing the emergence of drug resistance, and possibly eliminating the need for PEG-IFN +/- ribavirin. The combination of R7128/R7227 offers the potential for a highly potent regimen with a high genetic barrier to resistance. Methods: INFORM-1 is a randomized, double-blind, ascending dose Phase I trial.
Avatar m tn Nitazoxanide, brand name alinia, had also excellent ed50 results in an in vitro inhibition study, just as good as lamuvidine, so this sounded fascinating for a possible combination towards true synergism, to finally suppress virion production to a level so low that the silent daily reinfection will be reduced, allowing a slow net clearance of infected cells with a resulting drop in surface antigen.